Denali Therapeutics's total assets for Q3 2024 were $1.45B, a decrease of -3.23% from the previous quarter. DE:4DN total liabilities were $135.52M for the fiscal quarter, a 17.32% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.